Hoth Therapeutics Inc Stock Price, News & Analysis

Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced that Scientific Advisory Board member Michael Peter, Ph.D., published a whitepaper in bioRxiv focusing on COVID-19 SARS-CoV-2. The study utilizes computational modeling to analyze protein-protein binding interactions critical for viral entry, particularly regarding mutations in emerging variants. Hoth has previously secured a licensed agreement for peptide therapeutics targeting this interface to aid in COVID-19 treatment, with research guided by Dr. Peter. This work supports the development of therapeutic candidates against SARS-CoV-2 variants.

On February 8, 2021, Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced a partnership with Camargo Pharmaceutical Services. This collaboration aims to prepare and submit an Investigational New Drug (IND) application for their topical product, HT-001, to the U.S. FDA. The IND is anticipated to receive feedback by February 22, 2021, as Hoth conducts GLP toxicology studies. HT-001 targets skin disorders related to epidermal growth factor receptor inhibitors. The company aims to expedite the NDA submission process through a 505(b)(2) development pathway.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) updated shareholders on its therapeutic pipeline targeting dermatological conditions, COVID-19, and supportive care. Key developments include the BioLexa platform set to begin Phase 1b trials in Q1 2021, positive preclinical results for HT-003 targeting acne, and a Pre-IND meeting with the FDA for HT-001 scheduled for February 22, 2021. CEO Robb Knie emphasized the company’s strengthened balance sheet and optimistic outlook for 2021 as a pivotal growth year, aiming to drive shareholder value through continued advancements in its diverse portfolio.

On January 28, 2021, Hoth Therapeutics, Inc. (HOTH) announced an extension of its research collaboration with Weill Cornell Medicine for HT-003, a novel treatment for acne. This one-year extension follows positive initial results from prior studies indicating HT-003's therapeutic effects on acne-related signaling pathways. The collaboration aims to further investigate HT-003's mechanism and safety in murine models. Dr. Jonathan Zippin will lead the research, underscoring the commitment to developing effective therapies for dermatological conditions.

Hoth Therapeutics (NASDAQ: HOTH) announced the appointment of Dr. Mario Lacouture to its Scientific Advisory Board on January 27, 2021. Dr. Lacouture, a leader in treating skin toxicities from cancer therapies, will oversee the development of HT-001, a topical treatment aimed at managing skin disorders related to epidermal growth factor receptor inhibitor therapy. CEO Robb Knie expressed optimism about leveraging Dr. Lacouture's expertise to advance the clinical program for HT-001, enhancing Hoth's potential therapeutic offerings.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced promising in vitro findings for HT-003, a potential acne treatment. The research shows that HT-003 significantly inhibits the TLR2 pathway, crucial for acne pathophysiology, and reduces the expression of inflammatory markers in human skin cells. Lead researcher Dr. Jonathan Zippin highlights the drug's potential to benefit patients with various inflammatory skin conditions. Hoth continues to explore HT-003's therapeutic mechanisms through further in vitro studies and animal trials.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced that the FDA granted a Pre-IND meeting regarding HT-001, a topical treatment for rash and skin disorders in cancer patients. The meeting, requested on December 22, 2020, will provide FDA feedback on the drug development program, clinical trial designs, and necessary requirements. Feedback is expected by February 22, 2021. CEO Robb Knie expressed hope that the feedback will help expedite HT-001's transition to clinical trials, emphasizing the importance of these developments for the company's future.

On January 11, 2021, Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced a partnership with Charles River Laboratories to conduct preclinical studies for HT-001, a topical treatment aimed at alleviating rash and skin disorders from EGFR inhibitor cancer therapies. Six preclinical studies are planned, beginning with bioanalytical method development in Q1 2021. The studies aim to fulfill FDA requirements for clinical trial initiation. Hoth's CEO emphasized the collaboration's importance in addressing significant unmet needs in dermatological care.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) has announced a definitive securities purchase agreement for a private placement to institutional investors, expected to generate approximately $5.0 million in gross proceeds. Investors will acquire 2,475,248 shares of Common Stock at $2.02, along with warrants for an additional 1,237,624 shares at an exercise price of $2.25. The placement, facilitated by The Benchmark Company, LLC, is set to close on January 7, 2021, subject to customary conditions. The securities, not registered under the Securities Act, may not be resold in the U.S. without appropriate registration.